FDAnews Drug Daily Bulletin

Who Had the Buzz at the ADA Gathering? (Pharmalot blog)
“Against a backdrop of speculation over who would buy Amylin Pharmaceuticals and its Bydureon treatment, the annual American Diabetes Association [ADA] gathering was held this past weekend,” blogger Ed Silverman writes, “and, instead of focusing on takeover talk, the majority of the buzz was generated by old-fashioned study results.” Much of the buzz hovered around Johnson & Johnson, followed by Lilly and Novo Nordisk bringing up third in the hierarchy of the hive. “What catapulted J&J above its rivals was data from late-stage trials showing an experimental drug, called canagliflozin, demonstrated greater reduction in blood sugar than the Januvia, the widely prescribed Merck pill, and an older treatment, glimepiride,” Silverman writes.